133 related articles for article (PubMed ID: 11684408)
21. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.
Khoo SM; Shackleford DM; Porter CJ; Edwards GA; Charman WN
Pharm Res; 2003 Sep; 20(9):1460-5. PubMed ID: 14567642
[TBL] [Abstract][Full Text] [Related]
22. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.
Humberstone AJ; Porter CJ; Edwards GA; Charman WN
J Pharm Sci; 1998 Aug; 87(8):936-42. PubMed ID: 9687337
[TBL] [Abstract][Full Text] [Related]
23. Quantifying the Lymphatic Transport of Model Therapeutics from the Brain in Rats.
Hoang TA; Gracia G; Cao E; Nicolazzo JA; Trevaskis NL
Mol Pharm; 2024 May; 21(5):2473-2483. PubMed ID: 38579335
[TBL] [Abstract][Full Text] [Related]
24. Effect of bile on the oral absorption of halofantrine in polyethylene glycol 400 and polysorbate 80 formulations dosed to bile duct cannulated rats.
Tønsberg H; Holm R; Mu H; Boll JB; Jacobsen J; Müllertz A
J Pharm Pharmacol; 2011 Jun; 63(6):817-24. PubMed ID: 21585380
[TBL] [Abstract][Full Text] [Related]
25. Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation.
Brocks DR; Betageri GV
J Pharm Pharmacol; 2002 Aug; 54(8):1049-53. PubMed ID: 12195818
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS).
Michaelsen MH; Wasan KM; Sivak O; Müllertz A; Rades T
AAPS J; 2016 Jan; 18(1):180-6. PubMed ID: 26486790
[TBL] [Abstract][Full Text] [Related]
27. Clinical pharmacokinetics of halofantrine.
Karbwang J; Na Bangchang K
Clin Pharmacokinet; 1994 Aug; 27(2):104-19. PubMed ID: 7955774
[TBL] [Abstract][Full Text] [Related]
28. The impact of lymphatic transport on the systemic disposition of lipophilic drugs.
Caliph SM; Cao E; Bulitta JB; Hu L; Han S; Porter CJ; Trevaskis NL
J Pharm Sci; 2013 Jul; 102(7):2395-408. PubMed ID: 23696002
[TBL] [Abstract][Full Text] [Related]
29. Influence of bile on the absorption of halofantrine from lipid-based formulations.
Holm R; Tønsberg H; Jørgensen EB; Abedinpour P; Farsad S; Müllertz A
Eur J Pharm Biopharm; 2012 Jun; 81(2):281-7. PubMed ID: 22465095
[TBL] [Abstract][Full Text] [Related]
30. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
[TBL] [Abstract][Full Text] [Related]
31. The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins.
Brocks DR; Ramaswamy M; MacInnes AI; Wasan KM
Pharm Res; 2000 Apr; 17(4):427-31. PubMed ID: 10870986
[TBL] [Abstract][Full Text] [Related]
32. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs.
Lespine A; Chanoit G; Bousquet-Melou A; Lallemand E; Bassissi FM; Alvinerie M; Toutain PL
Eur J Pharm Sci; 2006 Jan; 27(1):37-43. PubMed ID: 16198549
[TBL] [Abstract][Full Text] [Related]
33. Lymphatic transport of puerarin occurs after oral administration of different lipid-based formulations to unconscious lymph duct-cannulated rats.
Zhou A; Lu T; Wang L; Lu C; Wang L; Wan M; Wu H
Pharm Dev Technol; 2014 Sep; 19(6):743-7. PubMed ID: 23978005
[TBL] [Abstract][Full Text] [Related]
34. An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat.
Griffin BT; O'Driscoll CM
Pharm Res; 2008 May; 25(5):1125-33. PubMed ID: 17975709
[TBL] [Abstract][Full Text] [Related]
35. A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs.
Holm R; Jørgensen EB; Harborg M; Larsen R; Holm P; Müllertz A; Jacobsen J
Eur J Pharm Sci; 2011 Mar; 42(4):416-22. PubMed ID: 21256961
[TBL] [Abstract][Full Text] [Related]
36. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.
Hauss DJ; Fogal SE; Ficorilli JV; Price CA; Roy T; Jayaraj AA; Keirns JJ
J Pharm Sci; 1998 Feb; 87(2):164-9. PubMed ID: 9519148
[TBL] [Abstract][Full Text] [Related]
37. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine.
Humberstone AJ; Porter CJ; Charman WN
J Pharm Sci; 1996 May; 85(5):525-9. PubMed ID: 8742945
[TBL] [Abstract][Full Text] [Related]
38. The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol.
Caliph SM; Faassen FW; Porter CJ
J Pharm Pharmacol; 2014 Oct; 66(10):1377-87. PubMed ID: 24821499
[TBL] [Abstract][Full Text] [Related]
39. Effects of polysorbate 80 on the in-vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats.
Tønsberg H; Holm R; Bisgaard J; Jacobsen J; Müllertz A
J Pharm Pharmacol; 2010 Jan; 62(1):63-70. PubMed ID: 20723000
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of an extended-dose halofantrine regimen in patients with malaria and in healthy volunteers.
Ohrt C; Watt G; Teja-Isavadharm P; Keeratithakul D; Loesuttiviboon L; Webster HK; Schuster B; Fleckenstein L
Clin Pharmacol Ther; 1995 May; 57(5):525-32. PubMed ID: 7768075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
